Tag Archive | "cetuximab"

Expert says Nivolumab Poised to Change Standard of Care in SCCHN

Wednesday, August 24, 2016

0 Comments

Source: www.onclive.com Author: Laura Panjwani Nivolumab (Opdivo) is a game-changing agent for the treatment of patients with squamous cell carcinoma of the head and neck (SCCHN), according to Robert L. Ferris, MD, PhD. “Recent findings have shown us that this agent is really the new standard-of-care option for all platinum-refractory patients with head and neck […]

Continue reading...

Nivolumab Improved Survival For Patients With Head and Neck Squamous Cell Carcinoma

Tuesday, April 19, 2016

0 Comments

Source: www.aacr.org Author: AACR Newsroom Staff   NEW ORLEANS — Treatment with the immunotherapeutic nivolumab (Opdivo) improved survival for patients with recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum-based chemotherapy compared with single-agent chemotherapy of the investigator’s choice, according to results from the CheckMate-141 phase III clinical trial presented here […]

Continue reading...

Immunotherapy Continues to Advance in Head and Neck Cancer

Monday, February 29, 2016

0 Comments

Source: www.onclive.com Author: Megan Garlapow, PhD   Concomitant administration of motolimod with cetuximab (Erbitux) increases the innate and adaptive immune response in the blood and the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC), overcoming negative prognostic biomarkers of cetuximab therapy alone, according to the biomarker data from a recent phase Ib clinical […]

Continue reading...

Immunotherapies gaining traction in head and neck cancers

Thursday, February 18, 2016

0 Comments

Source: www.targetedonc.com Author: Greg Kennelty An explosion of immunotherapies is on the horizon for patients with metastatic head and neck cancer, specifically as phase III trials begin to report findings for PD-1 inhibitors. This upcoming wave of new therapies places importance on understanding optimal treatment settings and adverse events associated with these therapies. In late […]

Continue reading...

Nivolumab Could Change Head and Neck Cancer Treatment Paradigm

Tuesday, February 16, 2016

0 Comments

Source: www.Targetedonc.com Author: Laura Panjwani   “To have an anti–PD-1 agent be proven to improve survival in head and neck cancer in a randomized phase III trial, and the potential for a new FDA approval in the near future is a game changer.” – Robert Ferris, MD, PhD With the phase III CheckMate-141 trial being […]

Continue reading...

Cetuximab plus RT linked with high toxicity in head and neck cancer

Sunday, December 13, 2015

0 Comments

Source: www.cancernetwork.com Author: Anna Azvolinsky, PhD The combination of radiation therapy plus the EGFR inhibitor cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) compared with radiation therapy plus the chemotherapy cisplatin, according to results of a phase II trial based in Italy. […]

Continue reading...

Follow-up by advance practice nurses improves care for patients with head, neck cancer

Tuesday, November 3, 2015

0 Comments

Source: www.healio.com Author: Anthony SanFilippo The launch of an advance practice nurse outpatient follow-up clinic improved symptom management for high-risk patients with head and neck cancer following radiation therapy, according to findings from a study conducted at Cleveland Clinic. This initiative led to fewer ED visits and hospital admissions, results showed. “These results are significant […]

Continue reading...

Keytruda doubles efficacy of only targeted therapy for head and neck cancer

Thursday, June 11, 2015

0 Comments

Source: www.curetoday.com Author: Lauren M. Green The immunotherapy Keytruda (pembrolizumab), in a recent study, proved twice as effective for the treatment of head and neck cancer as Erbitux (cetuximab), the only targeted therapy indicated as a therapy for the disease. The multisite study offers the largest experience to date of how immunotherapy can be deployed […]

Continue reading...

Merck immunotherapy appears effective in head and neck cancer – study | Reuters

Tuesday, June 2, 2015

0 Comments

Source: www.firstpress.com Author: Bill Berkrot   A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday. A quarter of the 132 patients who received the drug, […]

Continue reading...

AACR says that new drug may assist therapy for Head and Neck Cancer

Monday, September 22, 2014

0 Comments

Source: hcplive.com Author:    THURSDAY, Sept. 18, 2014 (HealthDay News) — The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association […]

Continue reading...